CVS Health Corp Company Profile (NYSE:CVS)

CVS Health Corp trades on the New York Stock Exchange (NYSE) under the ticker symbol "CVS."

CVS Health Corp declared a quarterly dividend on Thursday, March 2nd. Shareholders of record on Friday, April 21st will be paid a dividend of $0.50 per share on Monday, May 1st. This represents a $2.00 dividend on an annualized basis and a yield of 2.61%. The ex-dividend date of this dividend is Wednesday, April 19th. View CVS Health Corp's Dividend History.

CVS Health Corp (NYSE:CVS) announced its quarterly earnings results on Tuesday, May, 2nd. The company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.10 by $0.07. The company had revenue of $44.51 billion for the quarter, compared to analyst estimates of $44.20 billion. CVS Health Corp had a return on equity of 17.55% and a net margin of 3.00%. CVS Health Corp's quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.18 earnings per share. View CVS Health Corp's Earnings History.

CVS Health Corp is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for CVS Health Corp.

CVS Health Corp updated its FY17 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share guidance of $5.77-5.93 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.86. CVS Health Corp also updated its Q2 guidance to $1.29-1.33 EPS.

17 equities research analysts have issued 1-year price targets for CVS Health Corp's stock. Their forecasts range from $77.00 to $120.00. On average, they anticipate CVS Health Corp's stock price to reach $94.79 in the next twelve months. View Analyst Ratings for CVS Health Corp.

Here are some recent quotes from research analysts about CVS Health Corp stock:

• 1. Guggenheim analysts commented, " Our recent meetings with CEO Larry Merlo, CFO Dave Denton, and VP-IR Nancy Christal further reinforced our confidence in 10% secular growth, which we believe the market is currently undervaluing, at a 13x P/E on somewhat depressed 2017E EPS. Bottom line, even in the face of secular gross margin erosion, in both segments, we believe the company should be able to grow EBIT by 5% on the back of a) natural growth in specialty Rx, b) increasingly rapid product innovation, c) a broadening set of productive relationships, and d) both COGS and SG&A reductions. In our view, this growth merits a valuation closer to a market multiple'we reiterate our Buy rating and $90 PT, implying 15% upside from current levels." (3/28/2017)
• 2. Evercore ISI analysts commented, "While the quarter proved generally uneventful and guidance was reiterated on the surface (albeit some moving parts below ' dollar profit targets were unchanged in our view ' much of the delta related to where 4Q came out vs mid-point and lower inflation outlook), investors have reacted negatively to the lack of clarity on several key issues with respect to business model risk that in our minds is unlikely to dissipate until later in the year. We think management did an admirable job on the DIR fee issue and a reasonable job on gross to net / rebates, but the reality is that policy noise is unlikely to dissipate and the outlook for 2018 won't start to gain clarity until the summer. We think once we get initial color on the PBM selling season, a better understanding of underlying pharmacy share shifts and profit headwinds and ultimately gain a better picture of 2018 the multiple may start to see some relief. Until then CVS shares remain inexpensive and highly leveraged to tax reform and it appears as if many years of execution are being overshadowed by a tough 18 month stretch. Given how far shares have fallen and in our view strong FCF yield support we retain our Buy rating but acknowledge the path to returns from here is likely most appropriate for those with a multi-year time horizon and a 'deep value' focus." (2/9/2017)
• 3. According to Zacks Investment Research, "CVS Health posted better-than-expected second-quarter with respected to adjusted EPS. However, revenues missed the Zacks Consensus Estimate. The company’s Pharmacy Services segment continues to benefit from growth in the Specialty Pharmacy business while the Retail Pharmacy segment is gaining from increased same-store sales. We take note of the recently completed Omnicare and Target Pharmacy buyouts which, according to CVS, are strategically perfect fits. CVS Health expects to benefit with multiple opportunities for driving enterprise value from Omnicare and Target in both the near and long term. CVS Health also expects to see market share gain in its specialty pharmacy suite of services with differentiated specialty offerings providing a high level of clinical support to patients. However, the competitive landscape remains tough. The tussle for market share gain in the PBM and retail space also warrants caution." (8/3/2016)

CVS Health Corp saw a drop in short interest in April. As of April 28th, there was short interest totalling 24,632,038 shares, a drop of 14.7% from the April 13th total of 28,874,584 shares. Based on an average daily volume of 6,328,688 shares, the days-to-cover ratio is presently 3.9 days. Approximately 2.4% of the company's shares are short sold.

Some companies that are related to CVS Health Corp include Anthem (ANTM), Aetna (AET), CIGNA (CI), Express Scripts Holding Company (ESRX), Humana (HUM), Centene Corp (CNC), WellCare Health Plans (WCG), Health Net (HNT), Molina Healthcare (MOH), Magellan Health (MGLN), Health Insurance Innovations (HIIQ), Connecture (CNXR) and Universal American (UAM).

CVS Health Corp's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.12%), BlackRock Inc. (6.00%), State Street Corp (4.32%), FMR LLC (2.33%), Bank of America Corp DE (2.20%) and Massachusetts Financial Services Co. MA (1.86%). Company insiders that own CVS Health Corp stock include Andrew Sussman, C David Brown II, David M Denton, Eva C Boratto, Jonathan C Roberts, Larry J Merlo, Lisa Bisaccia, Stephen J Gold and Troyen A Brennan. View Institutional Ownership Trends for CVS Health Corp.

CVS Health Corp's stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, FMR LLC, Wellington Management Group LLP, Janus Capital Management LLC, Ameriprise Financial Inc., Massachusetts Financial Services Co. MA, Caisse DE Depot ET Placement DU Quebec and Alliancebernstein L.P.. Company insiders that have sold CVS Health Corp stock in the last year include Andrew Sussman, David M Denton, Eva C Boratto, Jonathan C Roberts and Troyen A Brennan. View Insider Buying and Selling for CVS Health Corp.

CVS Health Corp's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., LSV Asset Management, Vanguard Group Inc., Schroder Investment Management Group, St. James Investment Company LLC, Morgan Stanley, Swiss National Bank and Edgar Lomax Co. VA. View Insider Buying and Selling for CVS Health Corp.

Shares of CVS Health Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CVS Health Corp stock can currently be purchased for approximately $76.64.